Does Horizon Blue Cross Blue Shield of New Jersey Cover Metformin?

How Horizon BCBSNJ Formularies Work

Horizon BCBSNJ uses a tiered drug formulary system to organize how much members pay out of pocket for any given medication. Understanding this system is the fastest way to predict your actual cost at the pharmacy counter.

Tier Structure Overview

Most Horizon commercial plans use a four- or five-tier formulary:

| Tier | Category | Typical Cost Share | |------|----------|--------------------| | 1 | Preferred generics | $0, $15 copay | | 2 | Non-preferred generics | $10, $30 copay | | 3 | Preferred brand | $40, $70 copay | | 4 | Non-preferred brand | $70, $120 copay | | 5 | Specialty | 20 to 33% coinsurance |

Generic metformin hydrochloride sits in Tier 1 on the majority of Horizon commercial formularies reviewed for 2024 and 2025 plan years. Brand-name Glucophage lands in Tier 3 or Tier 4 on almost every plan, meaning the cost difference between generic and brand can exceed $100 per fill.

Plan Types That Include Metformin

Horizon BCBSNJ operates several distinct product lines, and metformin appears on the covered drug list for each one:

• Commercial PPO and EPO plans (individual, family, and employer-sponsored): Tier 1 generic.
• Horizon Medicare Advantage (including Horizon Omnia): Tier 1 or Tier 2 under Part D.
• NJ FamilyCare / Medicaid managed care administered by Horizon: $0 cost share for enrollees.
• NJ Direct (state employee): Tier 1 with $0, $5 copay for generics.

If you enrolled through the NJ Get Covered marketplace, the specific tier depends on the metal level you chose. Silver and Gold plans almost always place generic metformin in Tier 1, while some Bronze high-deductible plans require you to meet the deductible first, after which the copay drops to $0, $10.

Verifying Your Specific Plan's Coverage

The single most reliable way to confirm coverage is to search the Horizon BCBSNJ formulary tool at horizonblue.com using your plan ID. You can also call member services at 1-800-355-BLUE. Have your prescription label ready; the tool searches by drug name, strength, and dosage form.

Metformin: What It Is and Why Coverage Matters

Metformin is a biguanide oral medication approved by the FDA in 1994 for glycemic control in adults with Type 2 diabetes. [1] It remains the most prescribed antidiabetic drug in the United States, with roughly 92 million prescriptions dispensed annually according to IQVIA data cited by the CDC. [2]

Clinical Efficacy Data

The United Kingdom Prospective Diabetes Study (UKPDS 34, N=1,704 overweight patients) demonstrated that metformin reduced any diabetes-related endpoint by 32% compared to conventional diet therapy (P<0.001), and all-cause mortality by 36% (P<0.011). [3] That landmark 1998 trial remains the primary reason metformin holds first-line status in virtually every major diabetes guideline.

The American Diabetes Association (ADA) 2024 Standards of Medical Care in Diabetes states: "Metformin remains an effective, low-cost, and safe medication and should be continued if tolerated and not contraindicated in people with type 2 diabetes." [4]

Why Cost Is a Real Barrier

Even a $15 monthly copay compounds to $180 per year, and some members on Bronze or catastrophic plans pay full price until they satisfy a deductible that may reach $7,500. The Diabetes Care journal published data in 2022 showing that out-of-pocket drug costs above $30/month are independently associated with a 30% increase in medication non-adherence among lower-income patients with Type 2 diabetes. [5] Coverage tier placement is, therefore, not a trivial administrative detail.

Prior Authorization for Metformin

For the FDA-approved Type 2 diabetes indication, Horizon BCBSNJ does not require prior authorization (PA) for generic metformin. A valid prescription is all that is needed.

When PA Does Apply

PA requirements can appear in three situations:

1. Brand-name Glucophage or Glucophage XR: Horizon typically requires proof that the prescriber has a documented clinical reason to avoid the generic before approving the brand at a lower cost share.

2. Extended-release formulations at high doses: Some plans require step therapy (a trial of immediate-release metformin first) before covering ER versions beyond 1,500 mg/day.

3. Off-label indications: Prescriptions written for polycystic ovary syndrome (PCOS), pre-diabetes, or longevity/anti-aging are more likely to trigger a PA request or outright denial, because those uses carry varying levels of guideline support.

Step Therapy for Off-Label Uses

The ADA does support metformin for pre-diabetes in high-risk individuals, noting in its 2024 Standards that "metformin therapy for prevention of type 2 diabetes should be considered in adults with prediabetes, especially those aged 25 to 59 years with BMI >35 kg/m², fasting plasma glucose >110 mg/dL, or history of gestational diabetes." [4] If your prescriber documents this clinical rationale in the PA request, approval rates improve meaningfully.

For longevity use (the Targeting Aging with Metformin, or TAME trial is the key ongoing study here), Horizon BCBSNJ has no formal coverage policy as of the 2025 plan year, and coverage is generally not expected until FDA grants a formal aging-related indication.

The TAME Trial and Off-Label Longevity Use

The TAME trial (NCT03077282), funded by the American Federation for Aging Research, is a randomized, placebo-controlled study of metformin 1,500 mg/day in adults aged 65 to 79 without diabetes. [6] The primary endpoint is a composite of incident diabetes, cardiovascular events, cancer, dementia, and death. Enrollment exceeded 3,000 participants and the trial expects primary outcome data around 2026.

HealthRX Clinical Framework: When to Request Coverage for Off-Label Metformin

Before submitting a PA for longevity or pre-diabetes metformin use under a Horizon BCBSNJ plan, your prescribing provider should assemble the following documentation package:

1. Fasting glucose or HbA1c confirming pre-diabetic range (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%).
2. BMI measurement (Horizon is more likely to approve when BMI is >25 kg/m²).
3. A clinical note citing the ADA 2024 Standards recommendation for metformin in pre-diabetes prevention.
4. Any complicating risk factors: gestational diabetes history, first-degree family history of Type 2 diabetes, or documented metabolic syndrome.

This documentation package does not guarantee approval, but it shifts the PA from a speculative request to one grounded in published, guideline-endorsed evidence.

Cost If Horizon BCBSNJ Denies Coverage or Your Deductible Is Unmet

Denial or a high deductible does not mean you pay retail pharmacy prices. Several low-cost channels exist.

Mark Cuban Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists metformin hydrochloride 500 mg (180 tablets, equivalent to a 90-day supply at twice-daily dosing) for approximately $6.60 as of January 2025. No insurance is required. This price is often lower than the Tier 1 copay on some plans. [7]

GoodRx

GoodRx coupons typically bring generic metformin to $4, $12 for a 90-day supply at major New Jersey pharmacy chains including CVS, Walgreens, Rite Aid, and ShopRite. GoodRx cannot be combined with insurance on the same prescription; you must choose one or the other at the point of sale.

Walmart $4 Generic Program

Walmart's in-store pharmacy offers metformin 500 mg and 1,000 mg tablets for $4 per 30-day supply or $10 per 90-day supply through its generic prescription program, regardless of insurance status. This is available at New Jersey Walmart pharmacy locations.

340B Covered Entities in New Jersey

Federally Qualified Health Centers (FQHCs) and other 340B-eligible providers in New Jersey can dispense metformin at drastically reduced prices to qualifying low-income patients. The HRSA 340B database lists over 200 covered entities in New Jersey. [8]

How to Appeal a Coverage Denial

If Horizon BCBSNJ denies coverage for metformin (most commonly for a brand-name version or an off-label indication), New Jersey state law and federal ACA regulations give you clear appeal rights.

Internal Appeal

File an internal appeal within 180 days of the denial notice. Submit:

• A written appeal letter explaining the clinical rationale.
• A letter of medical necessity from your prescribing physician.
• Supporting literature (ADA guidelines, relevant trial data).

Horizon must respond to an urgent appeal within 72 hours and a standard appeal within 30 calendar days.

External Review

If the internal appeal fails, you may request an independent external review through the New Jersey Department of Banking and Insurance (DOBI). New Jersey is an ACA-compliant state, so external review is available for any denial involving medical necessity. The external reviewer is not employed by Horizon and must render a decision within 45 days for standard requests.

Expedited Review for Urgent Cases

For patients whose health would be significantly harmed by delay (for example, someone with uncontrolled HbA1c above 10% awaiting first-line therapy), an expedited appeal must be resolved within 72 hours under federal law (29 CFR 2590.715-2719).

Metformin vs. Newer Diabetes Drugs: Coverage Comparison Under Horizon BCBSNJ

Knowing where metformin sits relative to GLP-1 receptor agonists and SGLT-2 inhibitors helps you understand the formulary logic Horizon applies.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy), liraglutide (Victoza), and dulaglutide (Trulicity) all land in Tier 3 or Tier 4 on most Horizon commercial plans, with copays ranging from $60 to $200 per month after deductible. PA is required for all branded GLP-1 agents, and Horizon typically requires documented failure of metformin or a contraindication before approving GLP-1 therapy for Type 2 diabetes. For obesity (Wegovy, Zepbound), coverage depends entirely on whether the employer plan includes a weight-loss benefit rider. Many New Jersey employer plans do not include this rider.

In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% in the placebo group (P<0.001). [9] Despite this efficacy advantage over metformin for weight loss, the cost differential is substantial: metformin runs under $15/month while Wegovy lists above $1,300/month without insurance.

SGLT-2 Inhibitors

Empagliflozin (Jardiance) and dapagliflozin (Farxiga) sit in Tier 3 on most Horizon plans with copays around $45, $90/month. PA is not always required, but step therapy through metformin is standard. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% relative to placebo in patients with Type 2 diabetes and established cardiovascular disease. [10] For patients in that specific cardiovascular-risk category, a Horizon clinical exception request citing EMPA-REG OUTCOME data can justify combination therapy rather than metformin monotherapy.

DPP-4 Inhibitors

Sitagliptin (Januvia) and alogliptin (Nesina) are Tier 3 on most plans. Generic sitagliptin became available in 2023 and has moved to Tier 2 on some updated formularies at roughly $30, $50/month. These agents are generally approved after metformin monotherapy has proven insufficient.

Special Populations: PCOS, Gestational Diabetes History, and Pediatric Use

PCOS

Metformin is the most widely used off-label treatment for PCOS-related insulin resistance and menstrual irregularity. The Endocrine Society Clinical Practice Guideline on PCOS (2023 update) states metformin "may improve menstrual regularity and metabolic parameters in women with PCOS." [11] Horizon BCBSNJ does not list PCOS as a covered indication on most standard formularies, meaning a PA citing this guideline language is advisable before the prescription reaches the pharmacy.

Gestational Diabetes History

Women with a history of gestational diabetes (GDM) have a 50% lifetime risk of progressing to Type 2 diabetes, according to CDC surveillance data. [2] The ADA 2024 Standards recommend considering metformin for GDM-history patients who are in the pre-diabetic range. [4] Horizon coverage for this subgroup follows the same pre-diabetes PA pathway described above.

Patients Under 18

The FDA label for metformin includes pediatric use down to age 10 for Type 2 diabetes. Horizon BCBSNJ covers metformin for pediatric members with a Type 2 diabetes diagnosis without requiring PA, consistent with the FDA-approved label. For children under 10 or for off-label pediatric indications, PA is required.

Practical Steps to Confirm and Use Your Coverage

Getting coverage confirmed before you arrive at the pharmacy saves time and prevents the sticker-shock scenario where a pharmacist quotes you full retail price.

Step 1: Look Up Your Plan's Formulary

Log into your Horizon BCBSNJ member account at horizonblue.com. Under "Prescriptions," select "Drug Cost and Coverage." Enter "metformin" and your plan year. The tool returns the tier, any restrictions (PA, step therapy, quantity limits), and estimated cost per fill.

Step 2: Confirm the Prescriber Writes for Generic

Ask your provider to write the prescription as "metformin hydrochloride" without specifying brand. Some pharmacy software auto-switches to brand if the prescription reads "Glucophage," triggering a higher tier copay.

Step 3: Use a 90-Day Mail-Order Supply

Horizon's mail-order pharmacy (Horizon Pharmacy, powered by OptumRx for many plans) typically offers 90-day supplies of Tier 1 generics at a two-copay price (you pay for two months, get the third free). For metformin at $10/30-day, this brings annual cost to approximately $80 instead of $120.

Step 4: If Denied, File Immediately

The 180-day appeal window under New Jersey law starts from the date printed on the denial letter, not the date you receive it. Request a PA denial letter in writing from Horizon if you are told verbally that coverage is not available.

Key Safety Notes Your Prescriber Should Review

Metformin is generally well tolerated, but two contraindications are worth knowing because they affect whether the prescription will be written at all, not just whether it will be covered.

Renal Function Threshold

The FDA label was updated in 2016 to permit metformin use in patients with estimated glomerular filtration rate (eGFR) down to 30 mL/min/1.73 m². [1] Use is contraindicated when eGFR falls below 30. Horizon medical reviewers will sometimes request a recent creatinine or eGFR result as part of a PA review, particularly for older patients.

Contrast Dye Interaction

Metformin should be held for 48 hours after iodinated contrast media administration in patients with eGFR <60 mL/min/1.73 m², per the American College of Radiology guidelines. This does not affect coverage, but it affects prescription continuity for members undergoing imaging studies.

A 2022 meta-analysis in BMJ (N=52,413 participants across 17 studies) confirmed that lactic acidosis risk with metformin at therapeutic doses is extremely low, estimated at 3 cases per 100,000 patient-years, comparable to background population rates. [12]